Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Pharmacotherapy Considerations in Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting Publisher



Shahrami B1, 2 ; Biglari M2, 3 ; Kavehahangaran R1, 2 ; Rad S2, 3 ; Hadjibabaie M1 ; Vaezi M2, 3
Authors

Source: European Journal of Cancer Care Published:2023


Abstract

Objectives. Although several guidelines are available aiming for optimal chemotherapy-induced nausea and vomiting (CINV) control, there still remain critical therapeutic challenges: (i) recommendations are mainly drug-based, not protocol-based; (ii) the risk of antiemetics-related interactions is not highlighted; (iii) the emetogenicity of a regimen may vary over the cycle; and (iv) the impact of the underlying malignancy is overlooked. Apparently, the existing approach seems not to be generally efficient and puts patients at risk of insufficient use of antiemetics as well as poor emesis control. Evidence Acquisition. This study has re-evaluated the emetogenicity of chemotherapy regimens based on administered medications on each day, drug-drug interactions, combination therapy, and delayed CINV. Results. A literature review was done to re-evaluate the emetogenicity of the commonly accepted chemotherapy regimens based on administered medications on each day, drug interactions, combination therapy, and delayed CINV. Conclusion. The revised CINV prophylaxis protocols with sorted recommendations for hematologic malignancies and solid tumors have been represented, with respect to the availability of prophylactic medications. © 2023 Bita Shahrami et al.
Other Related Docs
7. Post-Marketing Surveillance of a Generic Oxaliplatin (Alvoxalⓡ) in Iranian Patients With Cancer, Current Therapeutic Research - Clinical and Experimental (2022)